Clinical trial
Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade…
NCT00168727 · Biogen, Industry · Completed
Key facts
| NCT number | NCT00168727 |
|---|---|
| Title | Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma |
| Official title | Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma |
| Lead sponsor | Biogen, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, Low-Grade |
| Intervention type | Drug |
| Interventions | ibritumomab tiuxetan (Zevalin®) |
| Enrollment | 12 |
| Start date | Jun 1, 2003 |
| Completion | Oct 31, 2005 |
| First posted | Sep 15, 2005 |
| Last update posted | Aug 23, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: